Sex differences in the drug therapy for oncologic diseases

Area of Science:

• Pharmacology
• Oncology
• Genetics

Background:

• Gender-specific differences exist in chemotherapy response rates and side effect probability.
• Sex-biased expression of metabolic enzymes and transporters affects pharmacokinetics of anti-cancer drugs, often leading to longer half-lives in women.
• These pharmacokinetic differences can result in improved survival but also increased toxicity in female patients.

Purpose of the Study:

• To review and summarize the gender-dependent differences in chemotherapy response, pharmacokinetics, and toxicity.
• To highlight how sex-based variations in drug metabolism, gene expression, and tissue properties influence treatment outcomes.
• To discuss the implications for novel therapies, including tyrosine kinase inhibitors and monoclonal antibodies.

Main Methods:

• Literature review and synthesis of existing research on gender differences in cancer treatment.
• Analysis of pharmacokinetic data, focusing on drug half-life and metabolism in relation to gender.
• Examination of organ-specific toxicities and side effect profiles, such as mucositis and nausea/vomiting, across genders.

Main Results:

• Chemotherapy protocols show variable efficacy and toxicity based on gender; some improve response in women without increasing toxicity (e.g., cisplatin), while others increase toxicity without improving response (e.g., 5-fluorouracil).
• Women exhibit increased sensitivity to certain agents and experience more severe organ-specific toxicities (e.g., cardiac, neurotoxicity) due to gender-specific gene expression.
• Novel therapies like monoclonal antibodies show longer half-lives and improved responses in women, while anti-emetic drugs are less effective in females, exacerbating nausea and vomiting.

Conclusions:

• Gender is a critical factor influencing chemotherapy efficacy, pharmacokinetics, and toxicity.
• Understanding sex-based biological differences is essential for optimizing cancer treatment strategies and minimizing adverse events.
• Personalized medicine approaches that account for gender are necessary for improving patient outcomes in oncology.